Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia
<b>Introduction</b><b>:</b> Ethiopia introduced a second dose of measles-containing vaccine (MCV2) in 2019 to provide further protection against measles and further progress toward elimination. However, the sub-optimal coverage of both MCV1 and MCV2 suggest challenges with va...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/7/702 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592833236697088 |
|---|---|
| author | Kalkidan Solomon Brooke N. Aksnes Abyot Bekele Woyessa Chala Gari Sadi Almea M. Matanock Monica P. Shah Paulos Samuel Bekana Tolera Birhanu Kenate Abebe Bekele Tesfaye Deti Getachew Wako Amsalu Shiferaw Yohannes Lakew Tefera Melkamu Ayalew Kokebie Tatek Bogale Anbessie Habtamu Teklie Wubie Aaron Wallace Ciara E. Sugerman Mirgissa Kaba |
| author_facet | Kalkidan Solomon Brooke N. Aksnes Abyot Bekele Woyessa Chala Gari Sadi Almea M. Matanock Monica P. Shah Paulos Samuel Bekana Tolera Birhanu Kenate Abebe Bekele Tesfaye Deti Getachew Wako Amsalu Shiferaw Yohannes Lakew Tefera Melkamu Ayalew Kokebie Tatek Bogale Anbessie Habtamu Teklie Wubie Aaron Wallace Ciara E. Sugerman Mirgissa Kaba |
| author_sort | Kalkidan Solomon |
| collection | DOAJ |
| description | <b>Introduction</b><b>:</b> Ethiopia introduced a second dose of measles-containing vaccine (MCV2) in 2019 to provide further protection against measles and further progress toward elimination. However, the sub-optimal coverage of both MCV1 and MCV2 suggest challenges with vaccine uptake. In this qualitative study, we explored barriers to the uptake of MCV2 among caregivers, community leaders, and healthcare workers (HCWs). <b>Method:</b> A qualitative study was conducted between mid-April and mid-May 2021. We selected ten woredas (districts) in the Oromia Region, Ethiopia, stratified by settlement type (urban/rural), MCV1 coverage (high ≥ 80%; low < 80%), and history of measles outbreaks between June 2019 and June 2020. Experiences surrounding barriers to MCV2 uptake were discussed via focus group discussions (FGDs) and in-depth interviews (IDIs) with caregivers of children 12–23 and 24–36 months and key informant interviews (KIIs) with HCWs who administer vaccines and with community leaders. Participants were recruited via snowball sampling. Recorded data were transcribed, translated to English, and analyzed using ATLAS.ti v.09. <b>Results:</b> Forty FGDs and 60 IDIs with caregivers, 60 IDIs with HCWs, and 30 KIIs with community leaders were conducted. Barriers among caregivers included lack of knowledge and awareness about MCV2 and the vaccination schedule, competing priorities, long wait times at health facilities, vaccine unavailability, negative interactions with HCWs, and transportation challenges. At the community level, trusted leaders felt they lacked adequate knowledge about MCV2 to address caretakers’ questions and community misconceptions. HCWs felt additional training on MCV2 would prepare them to better respond to caretakers’ concerns. Health system barriers identified included the lack of human, material, and financial resources to deliver vaccines and provide immunization outreach services, which caretakers reported as their preferred way of accessing immunization. <b>Conclusions:</b> Barriers to MCV2 uptake occur at multiple levels of immunization service delivery. Strategies to address these barriers include tools to help caretakers track appointments, enhanced community engagement, HCW training to improve provider–client interactions and MCV2 knowledge, and efforts to manage HCW workload. |
| format | Article |
| id | doaj-art-03afd5d178a548ad90710e9b26ea530b |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-03afd5d178a548ad90710e9b26ea530b2025-01-21T01:52:25ZengMDPI AGVaccines2076-393X2024-06-0112770210.3390/vaccines12070702Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of EthiopiaKalkidan Solomon0Brooke N. Aksnes1Abyot Bekele Woyessa2Chala Gari Sadi3Almea M. Matanock4Monica P. Shah5Paulos Samuel6Bekana Tolera7Birhanu Kenate8Abebe Bekele9Tesfaye Deti10Getachew Wako11Amsalu Shiferaw12Yohannes Lakew Tefera13Melkamu Ayalew Kokebie14Tatek Bogale Anbessie15Habtamu Teklie Wubie16Aaron Wallace17Ciara E. Sugerman18Mirgissa Kaba19Department of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, EthiopiaGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USAOromia Regional Health Bureau, Addis Ababa, EthiopiaMinistry of Health of Ethiopia, Addis Ababa, EthiopiaGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USAGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USAOromia Regional Health Bureau, Addis Ababa, EthiopiaOromia Regional Health Bureau, Addis Ababa, EthiopiaOromia Regional Health Bureau, Addis Ababa, EthiopiaOromia Regional Health Bureau, Addis Ababa, EthiopiaOromia Regional Health Bureau, Addis Ababa, EthiopiaUnited Nations International Children’s Emergency Fund, Addis Ababa, EthiopiaUnited Nations International Children’s Emergency Fund, Addis Ababa, EthiopiaMinistry of Health of Ethiopia, Addis Ababa, EthiopiaMinistry of Health of Ethiopia, Addis Ababa, EthiopiaAfrican Field Epidemiology Network, Addis Ababa, EthiopiaEthiopian Public Health Institute, Addis Ababa, EthiopiaGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USAGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA 30329, USADepartment of Preventive Medicine, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia<b>Introduction</b><b>:</b> Ethiopia introduced a second dose of measles-containing vaccine (MCV2) in 2019 to provide further protection against measles and further progress toward elimination. However, the sub-optimal coverage of both MCV1 and MCV2 suggest challenges with vaccine uptake. In this qualitative study, we explored barriers to the uptake of MCV2 among caregivers, community leaders, and healthcare workers (HCWs). <b>Method:</b> A qualitative study was conducted between mid-April and mid-May 2021. We selected ten woredas (districts) in the Oromia Region, Ethiopia, stratified by settlement type (urban/rural), MCV1 coverage (high ≥ 80%; low < 80%), and history of measles outbreaks between June 2019 and June 2020. Experiences surrounding barriers to MCV2 uptake were discussed via focus group discussions (FGDs) and in-depth interviews (IDIs) with caregivers of children 12–23 and 24–36 months and key informant interviews (KIIs) with HCWs who administer vaccines and with community leaders. Participants were recruited via snowball sampling. Recorded data were transcribed, translated to English, and analyzed using ATLAS.ti v.09. <b>Results:</b> Forty FGDs and 60 IDIs with caregivers, 60 IDIs with HCWs, and 30 KIIs with community leaders were conducted. Barriers among caregivers included lack of knowledge and awareness about MCV2 and the vaccination schedule, competing priorities, long wait times at health facilities, vaccine unavailability, negative interactions with HCWs, and transportation challenges. At the community level, trusted leaders felt they lacked adequate knowledge about MCV2 to address caretakers’ questions and community misconceptions. HCWs felt additional training on MCV2 would prepare them to better respond to caretakers’ concerns. Health system barriers identified included the lack of human, material, and financial resources to deliver vaccines and provide immunization outreach services, which caretakers reported as their preferred way of accessing immunization. <b>Conclusions:</b> Barriers to MCV2 uptake occur at multiple levels of immunization service delivery. Strategies to address these barriers include tools to help caretakers track appointments, enhanced community engagement, HCW training to improve provider–client interactions and MCV2 knowledge, and efforts to manage HCW workload.https://www.mdpi.com/2076-393X/12/7/702measlesmeasles vaccinebarrierqualitativeEthiopia |
| spellingShingle | Kalkidan Solomon Brooke N. Aksnes Abyot Bekele Woyessa Chala Gari Sadi Almea M. Matanock Monica P. Shah Paulos Samuel Bekana Tolera Birhanu Kenate Abebe Bekele Tesfaye Deti Getachew Wako Amsalu Shiferaw Yohannes Lakew Tefera Melkamu Ayalew Kokebie Tatek Bogale Anbessie Habtamu Teklie Wubie Aaron Wallace Ciara E. Sugerman Mirgissa Kaba Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia Vaccines measles measles vaccine barrier qualitative Ethiopia |
| title | Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia |
| title_full | Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia |
| title_fullStr | Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia |
| title_full_unstemmed | Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia |
| title_short | Qualitative Insights on Barriers to Receiving a Second Dose of Measles-Containing Vaccine (MCV2), Oromia Region of Ethiopia |
| title_sort | qualitative insights on barriers to receiving a second dose of measles containing vaccine mcv2 oromia region of ethiopia |
| topic | measles measles vaccine barrier qualitative Ethiopia |
| url | https://www.mdpi.com/2076-393X/12/7/702 |
| work_keys_str_mv | AT kalkidansolomon qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT brookenaksnes qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT abyotbekelewoyessa qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT chalagarisadi qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT almeammatanock qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT monicapshah qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT paulossamuel qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT bekanatolera qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT birhanukenate qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT abebebekele qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT tesfayedeti qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT getachewwako qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT amsalushiferaw qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT yohanneslakewtefera qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT melkamuayalewkokebie qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT tatekbogaleanbessie qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT habtamutekliewubie qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT aaronwallace qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT ciaraesugerman qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia AT mirgissakaba qualitativeinsightsonbarrierstoreceivingaseconddoseofmeaslescontainingvaccinemcv2oromiaregionofethiopia |